MOTS-C 20mg

MOTS-C 20mg

Product Overview and Research Information

MOTS-C 20mg is a product listing for MOTS-c, a mitochondrial-derived peptide studied in scientific research involving cellular signalling, metabolic regulation and stress responses. The 20mg quantity is stated in the product name; the exact format, brand, packaging and batch specifications have not been provided and should be verified before publication. This page presents the compound’s scientific background without treating experimental findings as established human benefits or making unsupported product-quality claims.

Product Overview

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Published research describes it as a peptide comprising 16 amino acids and encoded by a short open reading frame in the mitochondrial genome. Its discovery expanded scientific interest in mitochondria as sources of signalling molecules, rather than viewing them solely as cellular energy-producing structures. The original research is available through PubMed’s record of the MOTS-c discovery paper.

PubMed

The product name MOTS-C 20mg identifies the compound and a stated quantity, but it does not establish whether the product is supplied as a vial, powder, solution or another format. The brand is also unspecified. Customers should be able to review the actual product label and supporting documentation to confirm the identity, quantity basis, presentation and intended use.

If this item is genuinely offered as a research material, its intended purpose should be clearly described as research use only where applicable. That wording must reflect the actual product and does not, by itself, establish its regulatory classification or make every form of supply lawful.

Why Choose This Product?

When evaluating MOTS-C 20mg, buyers should look for clear product identification and evidence-backed specifications rather than promises about biological outcomes.

A well-prepared product listing should make the following information available where it has been verified:

• Compound identity: confirmation that the material is MOTS-c.

• Declared quantity: clarification of what the stated 20mg represents.

• Product format: an accurate description of the material supplied.

• Packaging and label: details matching the actual product received.

• Supplier or manufacturer: identification where available and verified.

• Batch documentation: genuine records that can be linked to the relevant batch.

• Analytical information: a Certificate of Analysis or test report only if it exists and its scope is clear.

• Intended use: an accurate statement consistent with the product’s actual classification and applicable requirements.

No brand name, purity percentage, independent-testing claim or manufacturing certification has been supplied for this listing. These details should not be added simply to make the product appear more premium. Transparent, specific information is a stronger basis for customer confidence.

Research Information

Scientific interest in MOTS-c includes its relationship to cellular signalling and pathways involved in metabolic regulation. The original 2015 study identified MOTS-c as a 16-amino-acid mitochondrial-derived peptide and investigated its biological activity in experimental systems, including animal models. Those findings are preclinical and must not be interpreted as proof of a treatment, preventive effect or guaranteed outcome in humans.

PubMed

A later review examined research into MOTS-c and its proposed mechanisms in stress responses, metabolism and ageing-related biological processes. The review provides context for ongoing scientific investigation, not verification of the composition or quality of any commercial MOTS-c product. Read the review through PubMed’s MOTS-c research overview.

PubMed

Researchers assessing this field may examine peptide structure, signalling pathways, experimental models, measurement methods and the reproducibility of published findings. Results depend on the specific study design and conditions. Scientific publications should therefore be read critically, and findings from one experimental setting should not be assumed to apply to a different setting or to a product with unverified specifications.

Quality and Trust

Peptide Depot should describe only documentation that is actually available for the product. Relevant evidence may include a specification sheet, batch identifier, manufacturer information and a batch-specific Certificate of Analysis. Where an analytical report exists, its stated methods, results, issuing organisation and limitations should be represented accurately.

At present, no product-specific evidence has been supplied to confirm purity, independent testing, manufacturing standards, certification, storage requirements or batch traceability for MOTS-C 20mg. Those claims should remain absent until supporting records have been checked.

Customers should also be able to locate accurate business contact information, checkout terms and shipping details. These store features should be described only as they exist on the live website; no claim of UK-based stock or a particular dispatch location should be made without confirmation.

Buying with Confidence in the UK

Before purchasing any research peptide, customers should review its identity, stated quantity, intended use and available documentation. They should distinguish published scientific literature about a compound from evidence about the specific material being sold.

The MHRA’s guidance on the supply of unlicensed medicinal products explains the regulatory framework for certain unlicensed medicines supplied for individual patients. It should not be interpreted as blanket permission to sell unlicensed products. The Human Medicines Regulations 2012 also set out requirements concerning the sale and supply of unauthorised medicinal products.

GOV.UK

+1

Important Research-Use Notice

If MOTS-C 20mg is confirmed to be a research material, label it “for research purposes only” where appropriate and describe its intended use accurately. Do not present it as a medicine or treatment, or claim established human benefits based on preclinical findings. Research-use wording alone does not determine regulatory status; the product’s classification and proposed supply must comply with applicable UK requirements.